Previous 10 | Next 10 |
Company Overview Autolus Therapeutics ( AUTL ) is a clinical-stage biotechnology company developing next-generation Chimeric Antigen Receptor (“CAR”) T cell therapies for the treatment of both hematological cancers and solid tumors. Using their broad suite of proprietary and ...
LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the 38 th ann...
Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL patients dosed with AUTO3 Investor call to be held December 9 at 8:30 am ET...
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome Data presented at 61 st American Society of Hematology Annual Meeting form basis for advancement of AUTO1 into pivotal clinical trial in adult ALL ...
LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review clinical data presented at the 61 st American Society of Hematolo...
Why is there never a headline that says "Government program ends as its intended goal has been achieved "?"- Oleg Atbashian Today, we look at an oncology concern from across the pond. The company recently came public, and like so many IPOs in the biotech sector these days, its IPO soon be...
The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2019 Q3 earnings Read more ...
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that Dr. Christian Itin, chairman and chief executive office...
Autolus Therapeutics (NASDAQ: AUTL ) inks an agreement with Tokyo-based Noile-Immune Biotech for rights to develop CAR T therapies using Noile's PRIME (proliferation-inducing and migration-enhancing) technology secreting both IL-7 and CCL19. More news on: Autolus Therapeutics plc, Heal...
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovati...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...